Biogen delivers a massive earnings surprise in Q2

Quote

anonymous

Guest
Biogen reported second-quarter earnings that surpassed Wall Street expectations. The company reported adjusted earnings of $9.15 per share, way ahead of the street projection of $7.53 per share. On a GAAP basis, earnings grew 88% to $7.85 per share.
Revenue grew 8% to $3.62 billion, surpassing the target of $3.47 billion set by analysts. The topline was primarily boosted by its Spinal Muscular Atrophy drug Spinraza as well as its biosimilars.
Revenue from Spinraza totaled $488 million in Q2, compared to $423 million a year ago. Meanwhile, biosimilar revenues increased to $184 million, compared to $127 million in Q2 of last year.

Source: Biogen (BIIB) Q2 2019 earnings results | AlphaStreet
 




anonymous said:
Biogen reported second-quarter earnings that surpassed Wall Street expectations. The company reported adjusted earnings of $9.15 per share, way ahead of the street projection of $7.53 per share. On a GAAP basis, earnings grew 88% to $7.85 per share.
Revenue grew 8% to $3.62 billion, surpassing the target of $3.47 billion set by analysts. The topline was primarily boosted by its Spinal Muscular Atrophy drug Spinraza as well as its biosimilars.
Revenue from Spinraza totaled $488 million in Q2, compared to $423 million a year ago. Meanwhile, biosimilar revenues increased to $184 million, compared to $127 million in Q2 of last year.

Source: Biogen (BIIB) Q2 2019 earnings results | AlphaStreet
Click to expand...

Where are the haters now?
 




anonymous said:
Where are the haters now?
Click to expand...

Oh I’m here Bi.atch. So the stock went up to $250. Whoop f,UC king woot. Imbecile do you realize the stock is nowhere where we were a year ago and only a few years back it was $450???? Stupid dumb ass you need t get your head out of your ass and realize we are in big trouble and soon we will go down to 1 TBM per territory and less RDs. Idiot! Enjoy the kool aid
 




anonymous said:
Where are the haters now?
Click to expand...
Ok, stock took a $10 bounce which is good. But read beyond the headline...Spinraza was off by $43 million, Tecfidera is still under pressure by Mylan's generic and overall, MS sales were flat. Biosimilars increased (good) but they're made and sold overseas so their growth is diluted.

Revenues were up... don't you see why? Sales were flat it's because new patients aren't being enrolled in prescriptions. The revenues are up because they keep increasing the prices on the already existing patients prescribed their treatments.

There's a lot more going on beyond the headline of that article. Read everything and understand it before you strut around like a proud peacock.
 




anonymous said:
Ok, stock took a $10 bounce which is good. But read beyond the headline...Spinraza was off by $43 million, Tecfidera is still under pressure by Mylan's generic and overall, MS sales were flat. Biosimilars increased (good) but they're made and sold overseas so their growth is diluted.

Revenues were up... don't you see why? Sales were flat it's because new patients aren't being enrolled in prescriptions. The revenues are up because they keep increasing the prices on the already existing patients prescribed their treatments.

There's a lot more going on beyond the headline of that article. Read everything and understand it before you strut around like a proud peacock.
Click to expand...

A $10 gain was wiped out in 2 days. People on this forum can say what they want and much of it is pretty accurate. The stock price is what the world really thinks of you. Great job Biogen, you threw day traders a bone.
 
















Top Bottom
Back
Quote